Copyright
©The Author(s) 2022.
World J Gastroenterol. Oct 14, 2022; 28(38): 5589-5601
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5589
Published online Oct 14, 2022. doi: 10.3748/wjg.v28.i38.5589
Table 1 Clinicopathological characteristics of different gastric cancer group
| SR group (n = 148) | NSR group (n =161) | P value | |
| Age (yr) | 57.15 ± 10.71 | 59.27 ± 11.52 | 0.2917 |
| Gender, n (%) | 0.781 | ||
| Male | 106 (71.6) | 113 (70.2) | |
| Female | 42 (28.4) | 48 (29.8) | |
| BMI (kg/m2) | 23.97 ± 3.591 | 23.68 ± 3.488 | 0.9716 |
| Neoadjuvant therapy, n (%) | 0.52 | ||
| Yes | 29 (19.6) | 27 (16.8) | |
| No | 119 (80.4) | 134 (83.2) | |
| Cardiovascular disease, n (%) | 0.503 | ||
| Yes | 32 (21.6) | 40 (24.8) | |
| No | 116 (78.4) | 121 (75.2) | |
| Diabetes, n (%) | 0.093 | ||
| Yes | 10 (6.8) | 20 (12.4) | |
| No | 138 (93.2) | 141 (87.6) | |
| T stage, n (%) | 0.699 | ||
| T1 and T2 | 23 (15.5) | 21 (13.0) | |
| T3 and T4 | 96 (64.9) | 113 (70.2) | |
| yp T1 and T2 | 5 (3.4) | 3 (1.9) | |
| yp T3 and T4 | 24 (16.2) | 24 (14.9) | |
| N stage, n (%) | 0.533 | ||
| N0 and N1 | 44 (29.7) | 51 (31.7) | |
| N2 and N3 | 75 (50.7) | 83 (51.6) | |
| yp N0 and yp N1 | 11 (7.4) | 15 (9.3) | |
| yp N2 and yp N3 | 18 (12.2) | 12 (7.5) | |
| M stage, n (%) | > 0.999 | ||
| M0 | 148 (100.00) | 161 (100) | |
| TNM stage, n (%) | 0.91 | ||
| Stage II | 57 (38.5) | 61 (37.9) | |
| Stage III | 91 (61.5) | 100 (62.1) | |
| Borrmann classification, n (%) | 0.207 | ||
| Superficial type | 3 (2.0) | 1 (0.6) | |
| Type I | 10 (6.8) | 9 (5.6) | |
| Type II | 41 (27.7) | 36 (22.4) | |
| Type III | 73 (49.3) | 78 (48.4) | |
| Type IV | 2 (1.4) | 9 (5.6) | |
| NA | 19 (12.8) | 28 (17.4) | |
| Lauren classification, n (%) | 0.782 | ||
| Intestinal type | 42 (28.4) | 48 (29.8) | |
| Diffuse type | 64 (43.2) | 69 (42.9) | |
| Mixed type | 34 (23.0) | 39 (24.2) | |
| NA | 8 (5.4) | 5 (3.1) | |
| Differentiation, n (%) | 0.666 | ||
| Low | 88 (59.5) | 91 (56.5) | |
| Low-medium | 36 (24.3) | 39 (24.2) | |
| Medium | 19 (12.8) | 26 (16.1) | |
| Medium-high and high | 2 (1.4) | 4 (2.5) | |
| NA | 3 (2.0) | 1 (0.6) | |
| Nerve invasion, n (%) | 0.26 | ||
| Yes | 73 (49.3) | 92 (57.1) | |
| No | 24 (16.2) | 27 (16.8) | |
| NA | 51 (34.5) | 42 (26.1) | |
| Vascular tumor thrombus, n (%) | 0.23 | ||
| Yes | 57 (38.5) | 57 (38.5) | |
| No | 40 (27.0) | 54 (33.5) | |
| NA | 51 (34.5) | 42 (26.1) | |
| Pathological classification, n (%) | 0.481 | ||
| Signet-ring cell carcinoma | 45 (30.4) | 55 (34.2) | |
| Another adenocarcinoma | 103 (69.6) | 106 (65.8) | |
| Resection type, n (%) | 0.057 | ||
| Total gastrectomy | 53 (35.8) | 54 (33.5) | |
| Proximal gastrectomy | 7 (4.7) | 20 (12.4) | |
| Distal gastrectomy | 88 (59.5) | 87 (54.0) | |
| R0 resection | 148 (100.00) | 161 (100) | > 0.999 |
| Resected lymph nodes number | 39.21 ± 14.13 | 35.73 ± 13.53 | 0.0145 |
| Positive lymph nodes number | 7.393 ± 8.864 | 6.856 ± 9.743 | 0.2319 |
- Citation: Wu YZ, Wu M, Zheng XH, Wang BZ, Xue LY, Ding SK, Yang L, Ren JS, Tian YT, Xie YB. No long-term survival benefit with sustained-release 5-fluorouracil implants in patients with stages II and III gastric cancer. World J Gastroenterol 2022; 28(38): 5589-5601
- URL: https://www.wjgnet.com/1007-9327/full/v28/i38/5589.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i38.5589